<PAGE>
Exhibit 99
Viropharma Form S-3 Related to its Subordinated Convertible Notes
Exton, PA, August 21, 2000 - ViroPharma Incorporated (Nasdaq: VPHM) today
announced that the Securities and Exchange Commission has declared its
Registration Statement on Form S-3 (File No. 333-37960) effective as of August
21, 2000, registering the resale of its 6% Subordinated Convertible Notes due
March 1, 2007 and of shares of its common stock issuable upon conversion thereof
by certain holders of the Notes, pursuant to the Registration Rights Agreement
that ViroPharma entered into when the Notes were issued. No securities are being
issued or offered by ViroPharma in connection with this registration statement.
This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.
ViroPharma Incorporated is committed to the commercialization, development and
discovery of antiviral pharmaceuticals. The Company is focused on drug
development and discovery activities in viral diseases including viral
respiratory infection (VRI, a severe form of the common cold), hepatitis C and
RSV disease.
# # #
